Stelara, used to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, was Johnson & Johnson’s best-selling drug in 2023. It generated $10.9 billion in revenue last year. The list price for Stelara is $25,400 every 2 months. The patent for Stelara expired in 2023, but due to settlements Johnson & Johnson doesn’t expect generic competition until 2025.